STRIDES PHARMA SCI Latest Share Price (STAR)
TODAY IN ONE LINE
STAR slumped 5.6% on average volume, lagging Nifty's 0.1% move, with no exchange filing today, suggesting a market-driven move.
With a market cap of ₹9,622.83 Cr., it trades at a P/E of 16.50. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
STRIDES PHARMA SCI flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 54.4% YoY
- ●Reasonable ValuationTrading at a moderate P/E of 18.2x
- ●Promoter BuyingPromoters increased holdings by 1.09% QoQ
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Poor Capital ReturnsLow ROE of 5.6%
Latest STRIDES PHARMA SCI News
What changed recently?
Recent events, corporate actions, and announcements.
STRIDES PHARMA SCI valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for STRIDES PHARMA SCI, framed against the sector median so the premium or discount is obvious at a glance.
STRIDES PHARMA SCI trades at a P/E of 16.50× and P/B of 3.26×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
STRIDES PHARMA SCI technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for STRIDES PHARMA SCI — derived from the latest tape, not yesterday's close.
STRIDES PHARMA SCI last traded at ₹1,036.5 with an intraday range of ₹1,029.4–₹1,076.9 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹1036.50| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1160.80 | +124.30 | +11.99% |
| R3 | 1113.30 | +76.80 | +7.41% |
| R2 | 1095.10 | +58.60 | +5.65% |
| R1 | 1065.80 | +29.30 | +2.83% |
| PIVOT | 1047.60 | 11.10 | 1.07% |
| CURRENT | 1036.50 | — | — |
| S1 | 1018.30 | -18.20 | -1.76% |
| S2 | 1000.10 | -36.40 | -3.51% |
| S3 | 970.80 | -65.70 | -6.34% |
| S4 | 923.30 | -113.20 | -10.92% |
STAR is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹1029.4–₹1076.9
Trading Below opening range, showing Bearishness
STRIDES PHARMA SCI financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for STRIDES PHARMA SCI — consolidated or standalone — with margins, YoY growth and key ratios inline.
STRIDES PHARMA SCI reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹9,622.83 Cr. and reported EPS of ₹17.02.
| Metric | Mar 2026 | May 2026 |
|---|---|---|
| Revenue from Operations | 4,859 | 4,859 ▲ 0.0% |
| Sales Growth YoY %Derived | 6.43% | 6.43% |
| Other Income | 151 | 151 ▲ 0.0% |
| Total Income | 5,009 | 5,009 ▲ 0.0% |
| 1,959 | 1,959 ▲ 0.0% | |
| Gross ProfitDerived | 2,900 | 2,900 ▲ 0.0% |
| Gross Margin %Derived | 59.69% | 59.69% |
| 1,975 | 1,975 ▲ 0.0% | |
| EBITDA (Operating Profit)Derived | 925 | 925 ▲ 0.0% |
| OPM %Derived | 19.04% | 19.04% |
| 354 | 354 ▲ 0.0% | |
| Profit Before Tax (PBT) | 668 | 668 ▲ 0.0% |
| 94 | 94 ▲ 0.0% | |
| Effective Tax %Derived | 14.09% | 14.09% |
| Profit/Loss from Discontinued Ops | — | — |
| Total Profit for Period | 575 | 575 ▲ 0.0% |
| Less: Non-controlling Interests | 18 | 18 ▲ 0.0% |
| Net Profit (Owner's PAT)Derived | 556 | 556 ▲ 0.0% |
| Net Profit Margin %Derived | 11.45% | 11.45% |
| PAT Growth YoY %Derived | -84.52% | -84.52% |
| Earnings Per Share (EPS ₹) | 60.34 | 60.34 ▲ 0.0% |
| Diluted Shares Outstanding (Cr) | 9 | 9 ▲ 0.0% |
| Share of Profit from Associates/JVs | 0 | 0 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | 44 | 44 ▲ 0.0% |
| Total Expenses (incl. D&A & Interest) | 4,341 | 4,341 ▲ 0.0% |
| Material Cost % of RevenueDerived | 32.09% | 32.09% |
| Employee Cost % of RevenueDerived | 19.12% | 19.12% |
| Other Cost % of RevenueDerived | 21.52% | 21.52% |
| Interest Coverage (x)Derived | 4.05x | 4.05x |
| Period | Mar 2018 | Jun 2018 | Mar 2019 | May 2019 | Mar 2020 | Jul 2020 | Mar 2021 | May 2021 | Mar 2022 | May 2022 | Mar 2023 | May 2023 | Mar 2024 | May 2024 | Mar 2025 | May 2025 | Mar 2026 | May 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 2,839 | 2,839 ▲ 0.0% | 3,012 ▲ 6.1% | 3,012 ▲ 0.0% | 2,752 ▼ 8.6% | 2,752 ▲ 0.0% | 3,316 ▲ 20.5% | 3,316 ▲ 0.0% | 3,070 ▼ 7.4% | 3,070 ▲ 0.0% | 3,688 ▲ 20.1% | 3,688 ▲ 0.0% | 4,051 ▲ 9.8% | 4,051 ▲ 0.0% | 4,565 ▲ 12.7% | 4,565 ▲ 0.0% | 4,859 ▲ 6.4% | 4,859 ▲ 0.0% | |
| Sales Growth YoY %Derived | — | — | 6.07% | — | -8.62% | — | 20.49% | — | -7.41% | -7.41% | 20.13% | 20.13% | 9.83% | 9.83% | 12.69% | 12.69% | 6.43% | 6.43% | |
| Other Income | 94 | 94 ▲ 0.0% | 45 ▼ 51.7% | 45 ▲ 0.0% | 53 ▲ 16.9% | 53 ▲ 0.0% | 51 ▼ 3.2% | 51 ▲ 0.0% | 132 ▲ 156.7% | 132 ▲ 0.0% | 90 ▼ 31.6% | 90 ▲ 0.0% | 40 ▼ 56.0% | 40 ▲ 0.0% | 59 ▲ 47.9% | 59 ▲ 0.0% | 151 ▲ 156.7% | 151 ▲ 0.0% | |
| Total Income | 2,933 | 2,933 ▲ 0.0% | 3,057 ▲ 4.2% | 3,057 ▲ 0.0% | 2,805 ▼ 8.2% | 2,805 ▲ 0.0% | 3,367 ▲ 20.0% | 3,367 ▲ 0.0% | 3,202 ▼ 4.9% | 3,202 ▲ 0.0% | 3,779 ▲ 18.0% | 3,779 ▲ 0.0% | 4,091 ▲ 8.3% | 4,091 ▲ 0.0% | 4,624 ▲ 13.0% | 4,624 ▲ 0.0% | 5,009 ▲ 8.3% | 5,009 ▲ 0.0% | |
1,379 | 1,379 ▲ 0.0% | 1,466 ▲ 6.3% | 1,466 ▲ 0.0% | 1,122 ▼ 23.4% | 1,122 ▲ 0.0% | 1,333 ▲ 18.7% | 1,333 ▲ 0.0% | 1,502 ▲ 12.7% | 1,502 ▲ 0.0% | 1,627 ▲ 8.3% | 1,627 ▲ 0.0% | 1,641 ▲ 0.8% | 1,641 ▲ 0.0% | 1,980 ▲ 20.7% | 1,980 ▲ 0.0% | 1,959 ▼ 1.1% | 1,959 ▲ 0.0% | ||
| Gross ProfitDerived | 1,461 | 1,461 ▲ 0.0% | 1,546 ▲ 5.8% | 1,546 ▲ 0.0% | 1,629 ▲ 5.4% | 1,629 ▲ 0.0% | 1,983 ▲ 21.7% | 1,983 ▲ 0.0% | 1,568 ▼ 20.9% | 1,568 ▲ 0.0% | 2,062 ▲ 31.5% | 2,062 ▲ 0.0% | 2,411 ▲ 16.9% | 2,411 ▲ 0.0% | 2,585 ▲ 7.2% | 2,585 ▲ 0.0% | 2,900 ▲ 12.2% | 2,900 ▲ 0.0% | |
| Gross Margin %Derived | 51.44% | 51.44% | 51.32% | 51.32% | 59.21% | 59.21% | 59.81% | 59.81% | 51.07% | 51.07% | 55.89% | 55.89% | 59.50% | 59.50% | 56.63% | 56.63% | 59.69% | 59.69% | |
1,064 | 1,064 ▲ 0.0% | 1,091 ▲ 2.5% | 1,091 ▲ 0.0% | 1,114 ▲ 2.1% | 1,114 ▲ 0.0% | 1,348 ▲ 21.1% | 1,348 ▲ 0.0% | 1,588 ▲ 17.8% | 1,588 ▲ 0.0% | 1,631 ▲ 2.7% | 1,631 ▲ 0.0% | 1,667 ▲ 2.2% | 1,667 ▲ 0.0% | 1,783 ▲ 6.9% | 1,783 ▲ 0.0% | 1,975 ▲ 10.8% | 1,975 ▲ 0.0% | ||
| EBITDA (Operating Profit)Derived | 397 | 397 ▲ 0.0% | 455 ▲ 14.7% | 455 ▲ 0.0% | 516 ▲ 13.4% | 516 ▲ 0.0% | 635 ▲ 23.1% | 635 ▲ 0.0% | -20 ▼ 103.2% | -20 ▲ 0.0% | 430 ▲ 2239.6% | 430 ▲ 0.0% | 743 ▲ 72.8% | 743 ▲ 0.0% | 803 ▲ 8.0% | 803 ▲ 0.0% | 925 ▲ 15.3% | 925 ▲ 0.0% | |
| OPM %Derived | 13.97% | 13.97% | 15.10% | 15.10% | 18.75% | 18.75% | 19.15% | 19.15% | -0.65% | -0.65% | 11.66% | 11.66% | 18.35% | 18.35% | 17.58% | 17.58% | 19.04% | 19.04% | |
307 | 307 ▲ 0.0% | 375 ▲ 22.1% | 375 ▲ 0.0% | 252 ▼ 32.8% | 252 ▲ 0.0% | 400 ▲ 58.8% | 400 ▲ 0.0% | 166 ▼ 58.5% | 166 ▲ 0.0% | 487 ▲ 193.7% | 487 ▲ 0.0% | 346 ▼ 29.0% | 346 ▲ 0.0% | 506 ▲ 46.1% | 506 ▲ 0.0% | 354 ▼ 30.0% | 354 ▲ 0.0% | ||
| Profit Before Tax (PBT) | 97 | 97 ▲ 0.0% | 120 ▲ 24.4% | 120 ▲ 0.0% | 162 ▲ 34.5% | 162 ▲ 0.0% | 373 ▲ 130.5% | 373 ▲ 0.0% | -542 ▼ 245.1% | -542 ▲ 0.0% | -1 ▲ 99.8% | -1 ▲ 0.0% | 59 ▲ 6511.3% | 59 ▲ 0.0% | 485 ▲ 725.1% | 485 ▲ 0.0% | 668 ▲ 37.8% | 668 ▲ 0.0% | |
10 | 10 ▲ 0.0% | 13 ▲ 34.8% | 13 ▲ 0.0% | 11 ▼ 13.6% | 11 ▲ 0.0% | 32 ▲ 179.4% | 32 ▲ 0.0% | -178 ▼ 663.2% | -178 ▲ 0.0% | -55 ▲ 69.0% | -55 ▲ 0.0% | 32 ▲ 157.1% | 32 ▲ 0.0% | 78 ▲ 145.4% | 78 ▲ 0.0% | 94 ▲ 21.5% | 94 ▲ 0.0% | ||
| Effective Tax %Derived | 10.06% | 10.06% | 10.90% | 10.90% | 7.00% | 7.00% | 8.48% | 8.48% | 32.91% | 32.91% | 6,030.64% | 6,030.64% | 53.73% | 53.73% | 15.98% | 15.98% | 14.09% | 14.09% | |
| Profit/Loss from Discontinued Ops | 610 | 610 ▲ 0.0% | 271 ▼ 55.6% | 271 ▲ 0.0% | -13 ▼ 104.7% | -13 ▲ 0.0% | 14 ▲ 209.2% | 14 ▲ 0.0% | — ▼ 100.0% | — | 19 | 19 ▲ 0.0% | 54 ▲ 192.0% | 54 ▲ 0.0% | 3,188 ▲ 5779.9% | 3,188 ▲ 0.0% | — ▼ 100.0% | — | |
| Total Profit for Period | 680 | 680 ▲ 0.0% | 330 ▼ 51.5% | 330 ▲ 0.0% | 31 ▼ 90.7% | 31 ▲ 0.0% | 258 ▲ 742.8% | 258 ▲ 0.0% | -474 ▼ 284.0% | -474 ▲ 0.0% | -212 ▲ 55.2% | -212 ▲ 0.0% | -94 ▲ 55.6% | -94 ▲ 0.0% | 3,598 ▲ 3914.4% | 3,598 ▲ 0.0% | 575 ▼ 84.0% | 575 ▲ 0.0% | |
| Less: Non-controlling Interests | 20 | 20 ▲ 0.0% | 5 ▼ 73.5% | 5 ▲ 0.0% | -6 ▼ 210.3% | -6 ▲ 0.0% | -11 ▼ 84.7% | -11 ▲ 0.0% | -14 ▼ 31.0% | -14 ▲ 0.0% | -10 ▲ 30.9% | -10 ▲ 0.0% | -24 ▼ 144.5% | -24 ▲ 0.0% | 4 ▲ 117.1% | 4 ▲ 0.0% | 18 ▲ 351.7% | 18 ▲ 0.0% | |
| Net Profit (Owner's PAT)Derived | 660 | 660 ▲ 0.0% | 325 ▼ 50.9% | 325 ▲ 0.0% | 36 ▼ 88.8% | 36 ▲ 0.0% | 268 ▲ 637.9% | 268 ▲ 0.0% | -460 ▼ 271.4% | -460 ▲ 0.0% | -203 ▲ 56.0% | -203 ▲ 0.0% | -71 ▲ 65.2% | -71 ▲ 0.0% | 3,593 ▲ 5188.9% | 3,593 ▲ 0.0% | 556 ▼ 84.5% | 556 ▲ 0.0% | |
| Net Profit Margin %Derived | 23.26% | 23.26% | 10.78% | 10.78% | 1.32% | 1.32% | 8.10% | 8.10% | -14.99% | -14.99% | -5.49% | -5.49% | -1.74% | -1.74% | 78.71% | 78.71% | 11.45% | 11.45% | |
| PAT Growth YoY %Derived | — | — | -50.85% | — | -88.79% | — | 637.88% | — | -271.44% | -271.44% | 55.97% | 55.97% | 65.15% | 65.15% | 5,188.87% | 5,188.87% | -84.52% | -84.52% | |
| Earnings Per Share (EPS ₹) | 73.80 | 73.80 ▲ 0.0% | 36.25 ▼ 50.9% | 36.25 ▲ 0.0% | 4.06 ▼ 88.8% | 4.06 ▲ 0.0% | 29.93 ▲ 637.2% | 29.93 ▲ 0.0% | -51.25 ▼ 271.2% | -51.25 ▲ 0.0% | -22.44 ▲ 56.2% | -22.44 ▲ 0.0% | -7.68 ▲ 65.8% | -7.68 ▲ 0.0% | 389.90 ▲ 5176.8% | 389.90 ▲ 0.0% | 60.34 ▼ 84.5% | 60.34 ▲ 0.0% | |
| Diluted Shares Outstanding (Cr) | 9 | 9 ▲ 0.0% | 9 ▲ 0.1% | 9 ▲ 0.0% | 9 ▲ 0.0% | 9 ▲ 0.0% | 9 ▲ 0.1% | 9 ▲ 0.0% | 9 ▲ 0.1% | 9 ▲ 0.0% | 9 ▲ 0.6% | 9 ▲ 0.0% | 9 ▲ 1.8% | 9 ▲ 0.0% | 9 ▲ 0.3% | 9 ▲ 0.0% | 9 ▲ 0.0% | 9 ▲ 0.0% | |
| Share of Profit from Associates/JVs | -17 | -17 ▲ 0.0% | -48 ▼ 187.6% | -48 ▲ 0.0% | -107 ▼ 121.9% | -107 ▲ 0.0% | -98 ▲ 8.8% | -98 ▲ 0.0% | -111 ▼ 13.3% | -111 ▲ 0.0% | -285 ▼ 157.4% | -285 ▲ 0.0% | -176 ▲ 38.4% | -176 ▲ 0.0% | 2 ▲ 101.0% | 2 ▲ 0.0% | 0 ▼ 74.5% | 0 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | -16 | -16 ▲ 0.0% | -64 ▼ 297.2% | -64 ▲ 0.0% | 37 ▲ 158.3% | 37 ▲ 0.0% | 17 ▼ 55.3% | 17 ▲ 0.0% | 49 ▲ 196.0% | 49 ▲ 0.0% | 8 ▼ 83.8% | 8 ▲ 0.0% | -55 ▼ 791.1% | -55 ▲ 0.0% | 150 ▲ 373.9% | 150 ▲ 0.0% | 44 ▼ 70.6% | 44 ▲ 0.0% | |
| Total Expenses (incl. D&A & Interest) | 2,837 | 2,837 ▲ 0.0% | 2,937 ▲ 3.5% | 2,937 ▲ 0.0% | 2,643 ▼ 10.0% | 2,643 ▲ 0.0% | 2,994 ▲ 13.3% | 2,994 ▲ 0.0% | 3,744 ▲ 25.0% | 3,744 ▲ 0.0% | 3,780 ▲ 1.0% | 3,780 ▲ 0.0% | 4,032 ▲ 6.7% | 4,032 ▲ 0.0% | 4,139 ▲ 2.7% | 4,139 ▲ 0.0% | 4,341 ▲ 4.9% | 4,341 ▲ 0.0% | |
| Material Cost % of RevenueDerived | 29.85% | 29.85% | 33.27% | 33.27% | 37.08% | 37.08% | 41.93% | 41.93% | 35.53% | 35.53% | 39.09% | 39.09% | 33.10% | 33.10% | 32.33% | 32.33% | 32.09% | 32.09% | |
| Employee Cost % of RevenueDerived | 15.29% | 15.29% | 14.70% | 14.70% | 16.08% | 16.08% | 16.59% | 16.59% | 21.07% | 21.07% | 19.85% | 19.85% | 18.54% | 18.54% | 18.90% | 18.90% | 19.12% | 19.12% | |
| Other Cost % of RevenueDerived | 22.19% | 22.19% | 21.53% | 21.53% | 24.38% | 24.38% | 24.07% | 24.07% | 30.65% | 30.65% | 24.38% | 24.38% | 22.62% | 22.62% | 20.15% | 20.15% | 21.52% | 21.52% | |
| Interest Coverage (x)Derived | 1.24x | 1.24x | 1.38x | 1.38x | 2.20x | 2.20x | 2.86x | 2.86x | -1.43x | -1.43x | 0.72x | 0.72x | 1.66x | 1.66x | 2.45x | 2.45x | 4.05x | 4.05x |
STRIDES PHARMA SCI segment analysis : revenue and profit mix.
Disclosed business segments at STRIDES PHARMA SCI with their share of revenue and profit, switchable between consolidated and standalone reporting.
STRIDES PHARMA SCI discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for STRIDES PHARMA SCI.
Our AI distills the core fundamental drivers supporting STRIDES PHARMA SCI, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
What you're getting.
No strengths or opportunities on record.
Key Risks.
No weaknesses or threats on record.
Flip Conditions.
Valuation risk. a P/E above 21 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
STRIDES PHARMA SCI peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — STRIDES PHARMA SCI is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
STRIDES PHARMA SCI chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for STRIDES PHARMA SCI — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
STRIDES PHARMA SCI delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for STRIDES PHARMA SCI over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in STRIDES PHARMA SCI stood at 44.3% of traded volume, against a 20-day average of 49.8%.
STRIDES PHARMA SCI announcements: results, concalls, ratings, M&A.
Filings STRIDES PHARMA SCI sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
STRIDES PHARMA SCI files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 140 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
Strides Pharma Science Limited has informed the Exchange about Schedule of meet
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Strides Pharma Science Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the…
Trading Window
Strides Pharma Science Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading)…
General Updates
Strides Pharma Science Limited has informed the Exchange about Sustainability Report for FY26.
General Updates
Strides Pharma Science Limited has informed the Exchange about completion of USFDA Inspection at the Company s Formulations Facility at Alathur
Investor decks & rating reports.
General Updates
General Updates
General Updates
Analysts/Institutional Investor Meet/Con. Call Updates
STRIDES PHARMA SCI dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue STRIDES PHARMA SCI has declared, sequenced by announce and record date.
STRIDES PHARMA SCI corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About STRIDES PHARMA SCI: business, sector, key facts.
What STRIDES PHARMA SCI does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
STRIDES PHARMA SCI operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: STAR, BSE: 532531.
Strides Pharma Science Limited (STAR) is a global pharmaceutical company engaged in the development, manufacturing, and sale of pharmaceutical products across diverse international markets, including Africa, Australia, North America, Europe, Asia, and India. The company's operations are divided into two main segments: Pharmaceutical and Biopharmaceutical, reflecting its diverse product portfolio and capabilities.
The Pharmaceutical segment focuses on the production and distribution of generic pharmaceutical products. These generics are available in a wide array of dosage forms, catering to various medical needs. This includes common forms like tablets, capsules (both hard and soft gelatin), sachets, and liquids, as well as more specialized forms such as nasal sprays, gels, powders, ointments, and creams. This broad range ensures the company can address a significant portion of the market demand for generic medications.
Beyond generics, Strides Pharma Science also develops and markets branded generic products. These branded generics focus on chronic therapies, targeting specific therapeutic areas. This includes women's health, central nervous system disorders, cardiovascular conditions, diabetes, dermatological issues, and probiotics. Several brand names, including Renerve, Unibrol, Combiart, Duotab, and Vitafer, highlight their commitment to branded products within these therapeutic areas. This strategy allows them to differentiate themselves in the market and potentially command premium pricing for certain products.
A significant portion of Strides Pharma Science's business also involves supplying medications for institutional use. This includes crucial drugs used to combat infectious diseases such as anti-retrovirals (used in HIV/AIDS treatment), anti-malarials, anti-tuberculosis medications, Hepatitis treatments, and others. This institutional business segment points to a strategic focus on serving public health needs, particularly in regions facing significant challenges related to infectious diseases.
In summary, Strides Pharma Science Limited operates a multifaceted business model encompassing the production and sale of both generic and branded generic pharmaceutical products across a wide range of therapeutic areas and dosage forms, serving both individual consumers and institutional clients globally. Their strategic focus on chronic therapies and infectious disease treatments underscores their commitment to addressing major health challenges worldwide.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Top Losers TodayScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about STRIDES PHARMA SCI (STAR).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of STRIDES PHARMA SCI (STAR)?
The current share price of STRIDES PHARMA SCI (STAR) is ₹1,036.50. Today, the stock has declined by ₹61.00 (5.56%), trading in a range of ₹1,029.40 to ₹1,076.90. The stock opened at ₹1,050.00 with a trading volume of 2,18,859 shares.
02Is STRIDES PHARMA SCI stock a good investment for long-term?
STRIDES PHARMA SCI can be considered for long-term investment based on several factors. The company has a market capitalization of ₹9,622.83 Cr., P/E ratio of 16.5, ROE of 5.59%, and ROCE of 4.43%. The dividend yield stands at 0.46%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of STRIDES PHARMA SCI stock?
The 52-week high price of STRIDES PHARMA SCI (STAR) is ₹1,260.90, while the 52-week low is ₹768.65. Currently trading at ₹1,036.50, the stock is 34.85% above its 52-week low and 17.8% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy STRIDES PHARMA SCI stock at the current price?
Whether to buy STRIDES PHARMA SCI stock at ₹1,036.50 depends on multiple factors. The stock is currently trading with a P/E ratio of 16.5 and P/B ratio of 3.26. Today's performance shows a loss of 5.56%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of STRIDES PHARMA SCI and when is the next dividend?
STRIDES PHARMA SCI offers a dividend yield of 0.46%, which means for every ₹100 invested at the current price of ₹1,036.50, you can expect to receive approximately ₹0.46 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of STRIDES PHARMA SCI?
STRIDES PHARMA SCI's key financial metrics include: P/E Ratio: 16.5, P/B Ratio: 3.26, ROE: 5.59%, ROCE: 4.43%, Dividend Yield: 0.46%, EPS: ₹17.02, Book Value: ₹341.68, and Debt-to-Equity: 0.35. The company's market cap stands at ₹9,622.83 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is STRIDES PHARMA SCI stock performing today in the market?
STRIDES PHARMA SCI stock opened at ₹1,050.00 and is currently trading at ₹1,036.50, showing a decline of ₹61.00 (5.56%). The intraday high is ₹1,076.90 and low is ₹1,029.40. The trading volume stands at 2,18,859 shares, indicating moderate market participation today.
08What is the P/E ratio of STRIDES PHARMA SCI and what does it indicate?
STRIDES PHARMA SCI has a Price-to-Earnings (P/E) ratio of 16.5, which means investors are willing to pay 16.50 for every ₹1 of earnings. With an EPS of ₹17.02, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about STRIDES PHARMA SCI (STAR) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.